NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

UCB SA (BR: UCB)

 
UCB Technical Analysis
5
As on 27th Jun 2025 UCB STOCK Price closed @ 170.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 139.64 & Strong Buy for SHORT-TERM with Stoploss of 99.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

UCBSTOCK Price

Open 169.50 Change Price %
High 172.95 1 Day 1.40 0.83
Low 169.40 1 Week 15.05 9.70
Close 170.20 1 Month 11.65 7.35
Volume 228287 1 Year 87.94 106.90
52 Week High 196.80 | 52 Week Low 81.78
 
BR Belgium Most Active Stocks
SCHD 25.71 2.72%
ABI 58.76 -0.51%
BOTHE 0.29 70.59%
AGFB 1.01 6.32%
ACPH 0.89 0.00%
OPTI 0.01 %
KBC 87.36 1.89%
UMI 12.60 0.48%
PROX 8.27 -1.90%
OXUR 0.03 %
 
BR Belgium Top Gainers Stocks
BOTHE 0.29 70.59%
CYAD 0.39 11.43%
CYAD 0.39 11.43%
AGFB 1.01 6.32%
CAMB 259.00 5.28%
CAMB 259.00 5.28%
FLOB 695.00 4.51%
SEQUA 1.27 4.10%
TITC 41.50 3.36%
TITC 41.50 3.36%
 
BR Belgium Top Losers Stocks
BELR 1.93 -74.27%
BELR 1.93 -74.27%
NEWT 1.80 -9.55%
NEWT 1.80 -9.55%
PIC 66.00 -6.25%
PIC 66.00 -6.25%
PIC 66.00 -6.25%
ZEN 185.00 -4.64%
ZEN 185.00 -4.64%
ZEN 185.00 -4.64%
 
 
UCB
Daily Charts
UCB
Intraday Charts
Whats New @
Bazaartrend
UCB
Free Analysis
 
UCB Important Levels Intraday
RESISTANCE177.04
RESISTANCE174.85
RESISTANCE173.49
RESISTANCE172.13
SUPPORT168.27
SUPPORT166.91
SUPPORT165.55
SUPPORT163.36
 
UCB Forecast June 2025
4th UP Forecast214.33
3rd UP Forecast200.18
2nd UP Forecast191.43
1st UP Forecast182.68
1st DOWN Forecast157.72
2nd DOWN Forecast148.97
3rd DOWN Forecast140.22
4th DOWN Forecast126.07
 
UCB Weekly Forecast
4th UP Forecast174.56
3rd UP Forecast173.16
2nd UP Forecast172.30
1st UP Forecast171.43
1st DOWN Forecast168.97
2nd DOWN Forecast168.10
3rd DOWN Forecast167.24
4th DOWN Forecast165.84
 
UCB Forecast2025
4th UP Forecast394.14
3rd UP Forecast322.32
2nd UP Forecast277.93
1st UP Forecast233.53
1st DOWN Forecast106.87
2nd DOWN Forecast62.47
3rd DOWN Forecast18.08
4th DOWN Forecast-53.74
 
 
UCB Other Details
Segment EQ
Market Capital 18890641408.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
UCB Address
UCB
 
UCB Latest News
 
Your Comments and Response on UCB SA
 
UCB Business Profile
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium. Address: AllEe de la Recherche, 60, Brussels, Belgium, 1070
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service